COgnitioN With VERiciGuat Evaluation in Heart Failure

Summary

CONVERGE-HF is a 4-center pilot phase IIb randomized control trial in ambulatory patients with chronic heart failure (≥ 6 months) and mild-to-moderate cognitive impairment.

Eligibility

Inclusion Criteria:

1. Adult patients
2. Established chronic heart failure (≥ 6 months)
3. Mild-to-moderate cognitive impairment (as per the diagnosis of cognitive impairment or a Montreal Cognitive Assessment (MoCA) score 10-25).

Exclusion Criteria:

1. Patients who have contraindications for sGC stimulator and vericiguat therapy (i.e. use of long-acting nitrates, other soluble guanylate cyclase stimulators (e.g., riociguat), or phosphodiesterase type 5 (PDE-5), pregnancy or breast-feeding)
2. Unable to undergo CMR imaging or brain MRI.
3. CMR exclusions: incompatible implantable cardiac device (ICD or CRT), uncontrolled atrial fibrillation or recurrent ventricular arrhythmias).
4. General medical conditions: uncontrolled thyroid disorders, hepatic failure, or myocardial revascularization procedures \[coronary angioplasty and/or surgical revascularization in the previous 3 months\], cancer/malignancy, or with severe dementia).
5. Patients with allergies to the study products.
6. Patients currently hospitalized.

Conditions3

Interventions1

Related trials

• A Study of Real-world Events of Vericiguat in Patients With Chronic Kidney Disease and Heart Failure — Guangdong Provincial People's Hospital
• Vericiguat and Reverse Remodeling Indices in Heart Failure — University Medical Centre Ljubljana
• SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery — Vanderbilt University Medical Center

Browse More Trials